Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) EBITDA (2017 - 2025)

Historic EBITDA for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $9.6 million.

  • Puma Biotechnology's EBITDA fell 5664.21% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.6 million, marking a year-over-year increase of 357.73%. This contributed to the annual value of $31.0 million for FY2024, which is 512.87% down from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's EBITDA is $9.6 million, which was down 5664.21% from $6.6 million recorded in Q2 2025.
  • Puma Biotechnology's EBITDA's 5-year high stood at $22.1 million during Q3 2024, with a 5-year trough of -$16.6 million in Q2 2021.
  • For the 5-year period, Puma Biotechnology's EBITDA averaged around $5.3 million, with its median value being $4.9 million (2023).
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 33331.46% in 2021, then soared by 209125.25% in 2022.
  • Over the past 5 years, Puma Biotechnology's EBITDA (Quarter) stood at -$503000.0 in 2021, then surged by 2091.25% to $10.0 million in 2022, then surged by 47.74% to $14.8 million in 2023, then fell by 9.68% to $13.4 million in 2024, then dropped by 28.37% to $9.6 million in 2025.
  • Its last three reported values are $9.6 million in Q3 2025, $6.6 million for Q2 2025, and $4.0 million during Q1 2025.